The surging anticipated demand for pulmonary hypertension drugs unveils a captivating landscape, where market share becomes the battleground for cutting-edge therapies, driving transformative advancements in the pursuit of improved patient outcomes.

Discover how upcoming drug disrupts the market share of existing drugs in the pulmonary arterial hypertension treatment landscape.